✅ Product Benefits

1. Dual mechanism of glycemic control — Combines an SGLT2 inhibitor (Empagliflozin) and a DPP‑4 inhibitor (Linagliptin) to enhance insulin release and increase glucose excretion while preserving renal threshold. 

2. Convenient once-daily dosing — One tablet per day (starting at 10/5 mg; may be increased to 25/5 mg if needed), improving adherence. 

   Flexible administration — Can be taken with or without food, offering greater convenience. 

3. Renal function considerations — Suitable for patients with eGFR ≥ 45 mL/min/1.73 m² without dose adjustment; contraindicated if eGFR <45. 

4. Cardiovascular mortality reduction potential — Empagliflozin component may lower risk of cardiovascular death in patients with type 2 diabetes and established cardiac disease. 

5. Low hypoglycemia risk unless combined — Minimal risk when used alone; risk increases if combined with insulin or sulfonylureas. 

6. Rapid onset of action — Glycemic improvement may begin within weeks; optimal control often achieved over several months. 

7. Affordable and widely accessible in Bangladesh — Priced around ৳3.00 per tablet (strip of 10 priced ৳30), and broadly available.